SF2959 (Legislative Session 94 (2025-2026))
Manufacturers interfering with access to 340B drugs prohibition extension
Related bill: HF2703
AI Generated Summary
Purpose of the Bill
The purpose of this bill is to ensure continued access to 340B drugs by extending prohibitions preventing drug manufacturers from interfering with such access. The 340B program is a federal initiative that allows eligible health care providers to purchase outpatient drugs at reduced prices, making them more affordable for patients.
Main Provisions
- The bill aims to repeal the expiration clause of an existing statute, Minnesota Statutes 2024 section 62J.96 subdivision 3, which currently limits the prohibition of manufacturer interference with the 340B drug program.
- By repealing this clause, the bill seeks to make the protection against interference permanent, beyond the current expiration date of July 1, 2027.
Significant Changes
- This legislation removes the expiration date, thereby extending indefinitely the statutory restrictions on drug manufacturers from interfering with healthcare providers' access to discount drugs under the 340B program.
Relevant Terms
340B drugs, drug manufacturers, interference, Minnesota Statutes, repeal, expiration.
Bill text versions
- Introduction PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 23, 2025 | Senate | Floor | Action | Introduction and first reading | |
| March 23, 2025 | Senate | Floor | Action | Introduction and first reading | |
| March 23, 2025 | Senate | Floor | Action | Referred to | Health and Human Services |
| March 26, 2025 | Senate | Floor | Action | Authors added |
Citations
[
{
"analysis": {
"added": [],
"removed": [
"Subdivision 3, which stated the section expires July 1, 2027."
],
"summary": "This bill repeals the expiration clause for access to 340B drugs under section 62J.96.",
"modified": []
},
"citation": "62J.96",
"subdivision": "subdivision 3"
}
]